María Eugenia Acevedo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Eugenia Acevedo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Fernández
Pharmaceutical Technology Department, Faculty of Pharmacy and Biochemistry, Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina
1 shared publication - Aldo Roberto Boccaccini
Institute of Biomaterials University of Erlangen‐Nuremberg Erlangen Germany
1 shared publication - Héctor Juan Prado
Pharmaceutical Technology Department, Faculty of Pharmacy and Biochemistry, Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina
1 shared publication - Juan Pablo Cattalini
Pharmaceutical Technology Department, Faculty of Pharmacy and Biochemistry, Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina
1 shared publication - Judith Anna Roether
Institute of Polymer Materials, University of Erlangen-Nuremberg, 91058 Erlangen, Germany
1 shared publication - Sofía Harriet
Pharmaceutical Technology Department, Faculty of Pharmacy and Biochemistry, Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 5 (2) , 31
Critical Attribute Considerations in Designing Systems for Sustained Topical Delivery of Hydrophobic Drugs for the Treatment of Acne Vulgaris
Background/Objectives: A matrix system for topical application was developed for a hydrophobic drug model, benzoyl peroxide (BPO), by turning it into its amorphous state to increase its bioavailability. BPO is commonly used to treat acne vulgaris; however, the commercially available products possess several drawbacks including poor absorption due to large crystal size and thus reduced efficacy and skin irritation. Methods: Several polymeric films containing amorphous BPO were successfully prepared for the first time from polymer + plasticizer colloidal dispersions and characterized. Results: The loaded BPO maintained its amorphous state even after 24 months of storage at 5 °C, and drug release could be modulated by adjusting the film compositions. The prepared films were obtained by solvent evaporation, and residual acetone remained below the level of quantification of the analytical method. In addition, the films were thin, flexible, transparent, bioadhesive, and able to remain on the skin for a clinically relevant period. Microscopic imaging confirmed a homogeneous and continuous morphology. Conclusions: The developed formulations may represent promising alternatives for the treatment of acne vulgaris.
- 6 May 2026
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 5 (2) , 31
Open AccessCritical Attribute Considerations in Designing Systems for Sustained Topical Delivery of Hydrophobic Drugs for the Treatment of Acne Vulgaris
Background/Objectives: A matrix system for topical application was developed for a hydrophobic drug model, benzoyl peroxide (BPO), by turning it into its amorphous state to increase its bioavailability. BPO is commonly used to treat acne vulgaris; however, the commercially available products possess several drawbacks including poor absorption due to large crystal size and thus reduced efficacy and skin irritation. Methods: Several polymeric films containing amorphous BPO were successfully prepared for the first time from polymer + plasticizer colloidal dispersions and characterized. Results: The loaded BPO maintained its amorphous state even after 24 months of storage at 5 °C, and drug release could be modulated by adjusting the film compositions. The prepared films were obtained by solvent evaporation, and residual acetone remained below the level of quantification of the analytical method. In addition, the films were thin, flexible, transparent, bioadhesive, and able to remain on the skin for a clinically relevant period. Microscopic imaging confirmed a homogeneous and continuous morphology. Conclusions: The developed formulations may represent promising alternatives for the treatment of acne vulgaris.